Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment

An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Keep Inspiring

Don’t let your disease define you

Immune-Based Therapies Emerge in Mantle Cell Lymphoma

February 24th 2020, 7:19pm

Article

Patients with the aggressive blood cancer can turn to immunotherapies like CAR-T cell therapy when disease recurs or becomes resistant.

FDA Grants Priority Review to CAR-T Cell Therapy for Mantle Cell Lymphoma

February 11th 2020, 7:00pm

Article

The Food and Drug Administration granted a priority review to KTE-X19 for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

The Use of Immunotherapy in Blood Cancer Treatment

February 7th 2020, 11:21pm

Video

Exciting Treatment Options Being Developed in Multiple Myeloma

February 7th 2020, 11:21pm

Video

Genetic Sequencing in Chronic Lymphocytic Leukemia

February 7th 2020, 11:21pm

Video

The Basics of Mantle Cell Lymphoma

February 7th 2020, 11:21pm

Video

Joining a Clinical Trial

February 7th 2020, 11:21pm

Video

CURE's Clinical Trial Corner: January 2020

January 30th 2020, 12:00am

Article

Here is a list of the recent trial initiations that occurred within the cancer space in January.

BTK Inhibitor Use Proves Beneficial in Mantle Cell Lymphoma Treatment

January 8th 2020, 12:00am

Video

Typically, the longer a patient with cancer is exposed to a drug the more side effects they experience, but in the case of Imbruvica, the opposite appears to be true for patients with MCL.

Phase 3 GRAVITAS-301 Study Fails to Improve Overall Responses in GVHD

January 7th 2020, 3:07am

Article

The pivotal phase 3 GRAVITAS-301 study – designed to evaluate itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease – failed to meet its primary endpoint of improving overall response rates.